ANA writes to Consumer Reports
This article was originally published in The Tan Sheet
Executive Summary
American Nutraceutical Association disputes Consumer Reports advice that consumers try least expensive chondroitin/glucosamine product meeting USP's 90% lower potency limit standard. Recommendation was conveyed in a review of joint health products published in magazine's January issue (1"The Tan Sheet" Dec. 17, 2001, p. 18). In a Jan. 24 letter, ANA contends review failed to mention bioavailability, citing a University of Maryland study which found many products that passed 90% potency test were not bioavailable. Without established bioavailability standards, ANA instead suggests consumers "find out which brand was used in [a successful study] and buy that"...